The United States Food and Drugs Administration (FDA) has approved the new targeted agent Sutent® (sunitinib malate) for treatment of gastrointestinal stromal tumors (GIST). The indication includes the use of Sutent for patients with GIST that has stopped responding to the standard treatment agent Gleevec® (imatinib mesylate) or for patients with GIST who cannot tolerate Gleevec. Sutent will be available for use on February 3, 2006.
GIST is a rare type of cancer that originates in the wall of the gastrointestinal track. The American Cancer Society estimates that only approximately 5,000 individuals are diagnosed annually with GIST in the U.S. GIST is thought to originate in the “pacemaker” cells of the digestive system, which are responsible for the movement of food or nutrients through the system.
Standard treatment for GIST typically includes the surgical removal of as much cancer as possible and treatment with the targeted agent Gleevec. Since GIST remains virtually unresponsive to standard chemotherapy and/or radiation therapy, effective treatment options are very limited. Subsequently, long-term survival remains suboptimal for many patients with GIST, particularly those who do not respond to Gleevec or those who stop responding to Gleevec.
Sutent is an oral targeted agent that works by inhibiting multiple biologic pathways involved in the growth, replication, and spread of cancer cells. Sutent deprives cancer cells of blood and nutrients needed for growth.
Mobocertinib Treatment for Non-Small Cell Lung Cancer with exon 20 Mutations
FDA grants breakthrough therapy status to Mobocertinib for treatment of patients with NSCLC and exon 20 mutations.
Tagrisso® - Standard of Care for EGFR + Non Small Cell Lung Cancer
FLAURA study confirms Tagrisso as best initial treatment of EGFR + NSCLC - learn more about its role in NSCLC management
The clinical trial that prompted the FDA approval included 312 patients with GIST whose disease had progressed during prior treatment with Gleevec or who were not able to tolerate treatment with Gleevec. Patients either received Sutent or placebo (inactive substitute). An interim analysis demonstrated that patients treated with Sutent achieved significantly improved outcomes compared to those who received placebo:
- Overall anticancer responses were achieved in 6.8% of patients treated with Sutent, compared to none of the patients who received placebo.
- Time before cancer progressed was 27 weeks for patients treated with Sutent, compared with 6 weeks for patients who received placebo.
- Progression-free survival was 24 weeks for patients treated with Sutent, compared with 6 weeks for patients who received placebo.
- Side effects mainly consisted of diarrhea, skin discoloration, mouth irritation, weakness, and altered taste.
Patients with GIST that has stopped responding to Gleevec and patients with GIST who are not able to tolerate Gleevec should speak with their physician regarding their individual risks and benefits of treatment with Sutent. Patients and physicians can call 1-877-744-5675 for information regarding patient assistance for those who don’t have prescription drug coverage and for information about reimbursement issues or appeals assistance.